Nuclear medicine theranostics comes of age

Funding

KH reports personal fees from Bayer and Sofie Biosciences; non-financial support from ABX; personal fees from Sirtex Medical, Adacap, Curium, Endocyte, Ipsen, Siemens Healthineers, GE Healthcare, Amgen, Novartis, and Y-mAbs Therapeutics; and grants and personal fees from BTG, all outside of the submitted work. BJK reports consulting fees from Advanced Accelerators Applications (Novartis), personal fees from PSI CRO, speakers fees from Advanced Accelerators Applications (Novartis), and participation on a Data Safety Monitoring Board and Advisory Board from ITM solucin (no payments). BH reports consulting fees from ABX, Bayer, Bristol Myers Squibb (clinical trial design and data review), Janssen (clinical trials), and Lightpoint Medical (product development); and financial support for attending meetings or travel from Astellas, AstraZeneca, and Janssen. JK reports consulting fees from Novartis and Pharamatrace; personal fees from Telix; financial support for attending meetings and travel from Ibsen; participation on a Data Safety Monitoring Board and Advisory Board from Novartis (personal fees); and payment for expert testimony by Sanofi. OS reports contracts to his institution from Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen,Lantheus, Merck, Progenics, and Tenebio; personal consulting fees for advising Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Merck, Myovant, Myriad, Noria Therapeutics, Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, and Theragnostics; Data Monitoring Committee fees for AstraZeneca, Bavarian Nordic, Janssen, Merck, and Pfizer; and stock or stock options from Clarity Pharmaceuticals and Noria. WJGO reports personal fees from Bayer and advisory board and speaker fees from Advanced Accelerator Applications (Novartis), all outside of the submitted work. HvP and JN’D declare no competing interests.